Independent report

Higher-risk patients eligible for COVID-19 treatments: independent advisory group report

皇冠体育app independent advisory group identified which patient groups are at highest risk of serious illness from COVID-19 and would benefit from new COVID-19 treatments.

From:
Department of Health and Social Care
Published
30 May 2022

Documents

Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report

HTML

Details

An updated version of this report was published in March 2023: Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (March 2023).

This report was commissioned by the Department of Health and Social Care (DHSC). DHSC asked the independent advisory group to identify a set of patient conditions based on who is at the highest risk of an adverse COVID-19 outcome, particularly hospitalisation and death.

皇冠体育app recommendations in the report have supported deployment of COVID-19 therapeutics in community settings, including oral antivirals and monoclonal antibodies. 皇冠体育app recommendations may also support work on other treatments in the future.

Updates to this page

Published 30 May 2022

Sign up for emails or print this page

Related content